Despite having gone through this before with her first son, Yusof, and despite the doctors explaining that this was a gene ...

The federal government has allocated $1.15 billion to long-covid research without any new treatments yet brought to market.

Hunter syndrome results from the absence of an enzyme needed to break down cellular waste. Without it, waste builds up in the body, causing progressive damage to various systems.

REGENXBIO (NASDAQ:RGNX) and Nippon Shinyaku have entered into a partnership for the development and commercialization of REGENXBIO's gene therapies RGX-121 for the treatment of Hunter syndrome, or MPS ...

One of the treatments, for a progressive disorder known as Hunter syndrome, could secure approval in the U.S. as soon as late ...

The partnership between REGENXBIO and Nippon Shinyaku is more than just a standard collaboration—it’s a bold, forward-looking venture aimed at bringing revolutionary gene therapies to market for rare, ...

REGENXBIO Inc. (RGNX) and Nippon Shinyaku announced a strategic partnership for the development and commercialization of RGX-121 for ...

Regenxbio (RGNX) and Nippon Shinyaku announced a strategic partnership for the development and commercialization of RGX-121 for the treatment ...

ROCKVILLE, MD, USA I January 14, 2025 I REGENXBIO Inc. (Nasdaq: RGNX) and Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) today announced a strategic partnership ...

That's because it recently received FDA Breakthrough Therapy Designation [BTD] for tividenofusp alfa [DNL310] for the treatment of patients with Hunter Syndrome [also known as MPS II]. Even better ...

Denali obtains Breakthrough Therapy Designation for its experimental candidate, tividenofusp alfa (DNL310), for the treatment of pateints with Hunter syndrome.

In 2021, the FDA granted Fast Track designation to tividenofusp alfa for the treatment of patients with Hunter syndrome. In 2022, the European Medicines Agency granted Priority Medicines ...